Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 5, 2000, Pages 510-521

  Chen, Mei Ling ^a   Lee, Sue Chih ^a   Ng, Moh Jee ^a   Schuirmann, Donald J ^a   Lesko, Lawrence J ^a   Williams, Roger L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ARYLBUTYRIC ACID DERIVATIVE; BETAXOLOL; CHLORTALIDONE; CIMETIDINE; ERYTHROMYCIN; FAMOTIDINE; GEMFIBROZIL; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; IBUPROFEN; KETOPROFEN; KETOROLAC TROMETAMOL; LORACARBEF; MESUXIMIDE; NAPROXEN; PHENYTOIN; PROCAINAMIDE; SPIRONOLACTONE; TACRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CONFIDENCE INTERVALS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHARMACOKINETICS; SEX CHARACTERISTICS; THERAPEUTIC EQUIVALENCY;

EID: 0033725193     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.111184     Document Type: Article

References (32)

1. Guideline for the study and evaluation of gender differences in clinical evaluation of drugs
2. Regulatory perspective of gender-based PK/PD variability in bioequivalence trials. Presented at FDA/OWH Workshop 'Gender Studies in Product Development: Scientific Issues and Approaches'
3. Women in bioavailability/bioequivalence trials - A regulatory perspective
4. Menstrual cycle effects on caffeine elimination in the human female
5. Influence of the menstrual cycle on theophylline pharmacokinetics in asthmatics
6. The influence of the menstrual cycle on the metabolism and clearance of methaqualone
7. Influence of the menstrual cycle on the absorption and elimination of D-xylose
8. The subject-by-formulation interaction as a criterion for interchangeability of drugs
9. Measuring switchability and prescribability: When is average bioequivalence sufficient?
10. Consideration of individual bioequivalence
11. Bioequivalence revisited
12. Individual variation and the acceptance of average bioequivalence
13. A method for the evaluation of individual bioequivalence
14. Extension to the use of tolerance intervals for the assessment of individual bioequivalence
15. Sample size considerations for assessing individual bioequivalence based on the method of tolerance interval
16. A simple approach for the evaluation of individual bioequivalence
17. A moment-based method for determining individual bioequivalence
18. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar
19. The assessment of individual and population bioequivalence
20. Towards a practical strategy for assessing individual bioequivalence
21. Mean difference vs. variability reduction: Tradeoffs in aggregate measures for individual bioequivalence
22. Individual bioequivalence - A regulatory update
23. Characterization of fluids from the stomach and proximal jejunum in men and women
24. Gender effects in pharmacokinetics and pharmacodynamics
25. Propranolol metabolism in normal subjects: Association with sex steroid hormones
26. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication
27. Gender-related differences in gastric emptying
28. Mechanistic aspects: The subject-by-formulation interaction